Catalyst Pharma (CPRX) Stock Forecast & Price Target

Compare

2,336 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CPRX Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Catalyst

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CPRX Stock 12 Month Forecast

Average Price Target

$33.33

▲(55.38%Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $33.33 with a high forecast of $35.00 and a low forecast of $31.00. The average price target represents a 55.38% change from the last price of $21.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","25":"$25","36":"$36","19.5":"$19.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,19.5,25,30.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.9,25.676923076923075,26.453846153846154,27.23076923076923,28.007692307692306,28.784615384615385,29.56153846153846,30.338461538461537,31.115384615384613,31.892307692307693,32.669230769230765,33.44615384615385,34.223076923076924,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.9,25.548461538461538,26.196923076923074,26.845384615384614,27.493846153846153,28.14230769230769,28.79076923076923,29.439230769230768,30.087692307692308,30.736153846153844,31.384615384615383,32.03307692307692,32.68153846153846,{"y":33.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.9,25.369230769230768,25.838461538461537,26.307692307692307,26.776923076923076,27.246153846153845,27.715384615384615,28.184615384615384,28.653846153846153,29.123076923076923,29.592307692307692,30.06153846153846,30.53076923076923,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.17,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.77,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.93,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$33.33

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$26

Buy

21.21%

Upside

Reiterated

06/18/25

Catalyst Pharma's overall stock score reflects its strong financial performance and strategic growth initiatives. While the technical indicators suggest caution, the company's robust earnings call and corporate events bolster its growth outlook. Valuation remains reasonable, providing a balanced view of potential risks and opportunities.

Samantha SemenkowCiti

Citi

$31

Buy

44.52%

Upside

Reiterated

05/13/25

Catalyst Pharma's Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating

Andrew FeinH.C. Wainwright

H.C. Wainwright

$35

Buy

63.17%

Upside

Reiterated

05/12/25

Catalyst Pharma's Strong Growth Prospects and Strategic Initiatives Drive Buy Rating

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Establishment Labs Holdings (ESTA), Catalyst Pharma (CPRX)

Jason GerberryBank of America Securities

Bank of America Securities

$34

Buy

58.51%

Upside

Reiterated

05/08/25

Joel BeattyRobert W. Baird

Robert W. Baird

$28→$32

Buy

49.18%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Leland GershellOppenheimer

Oppenheimer

$31→$32

Buy

49.18%

Upside

Reiterated

02/28/25

Catalyst Pharmaceutical Partners (CPRX) PT Raised to $32 at OppenheimerOppenheimer analyst Leland Gershell raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $32.00 (from $31.00) while maintaining a Outperform rating.

Sudan LoganathanStephens

Stephens

$33→$40

Buy

86.48%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$26

Buy

21.21%

Upside

Reiterated

06/18/25

Samantha SemenkowCiti

Citi

$31

Buy

44.52%

Upside

Reiterated

05/13/25

Catalyst Pharma's Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating

Andrew FeinH.C. Wainwright

H.C. Wainwright

$35

Buy

63.17%

Upside

Reiterated

05/12/25

Catalyst Pharma's Strong Growth Prospects and Strategic Initiatives Drive Buy Rating

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Establishment Labs Holdings (ESTA), Catalyst Pharma (CPRX)

Jason GerberryBank of America Securities

Bank of America Securities

$34

Buy

58.51%

Upside

Reiterated

05/08/25

Joel BeattyRobert W. Baird

Robert W. Baird

$28→$32

Buy

49.18%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Leland GershellOppenheimer

Oppenheimer

$31→$32

Buy

49.18%

Upside

Reiterated

02/28/25

Sudan LoganathanStephens

Stephens

$33→$40

Buy

86.48%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Catalyst Pharma

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+4.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +4.40% per trade.

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+7.33%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +7.33% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

19/26 ratings generated profit

Average Return

+42.59%

reiterated a buy rating 2 months ago

Copying Joon Lee's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +42.59% per trade.

2 Years

xxx

Success Rate

22/26 ratings generated profit

Average Return

+71.65%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +71.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CPRX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CPRX has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CPRX average Analyst price target in the past 3 months is 33.33.

Each month's total comprises the sum of three months' worth of ratings.

CPRX Financial Forecast

CPRX Earnings Forecast

Next quarter’s earnings estimate for CPRX is $0.39 with a range of $0.32 to $0.42. The previous quarter’s EPS was $0.45. CPRX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year CPRX has Preformed in-line its overall industry.

CPRX Sales Forecast

Next quarter’s sales forecast for CPRX is $140.44M with a range of $136.06M to $146.14M. The previous quarter’s sales results were $141.42M. CPRX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year CPRX has Preformed in-line its overall industry.

CPRX Stock Forecast FAQ

What is CPRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Catalyst Pharma’s 12-month average price target is 33.33.

What is CPRX’s upside potential, based on the analysts’ average price target?

Catalyst Pharma has 55.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CPRX a Buy, Sell or Hold?

Catalyst Pharma has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Catalyst Pharma’s price target?

The average price target for Catalyst Pharma is 33.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $31.00. The average price target represents 55.38% Increase from the current price of $21.45.

What do analysts say about Catalyst Pharma?

Catalyst Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of CPRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Catalyst Pharma (CPRX) Stock Forecast & Price Target

CPRX Analyst Ratings

CPRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Catalyst Pharma

CPRX Analyst Recommendation Trends

CPRX Financial Forecast

CPRX Earnings Forecast

CPRX Sales Forecast

CPRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts